Assenagon Asset Management
CHRS icon

Assenagon Asset Management’s Coherus Oncology CHRS Stock Holding History

Assenagon Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-91,886
Closed -$1.27M – 1301
2021
Q2 		$1.27M Buy
91,886
+16,370
+22% +$232K ﹤0.01% 870
2021
Q1 		$1.1M Buy
75,516
+12,577
+20% +$214K ﹤0.01% 912
2020
Q4 		$1.09M Buy
62,939
+15,400
+32% +$274K ﹤0.01% 718
2020
Q3 		$872K Sell
47,539
-2,527
-5% -$47K ﹤0.01% 872
2020
Q2 		$894K Buy
+50,066
New +$847K 0.01% 830

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Assenagon Asset Management's CHRS Position: Q3 2021 in Review

Assenagon Asset Management sold out of Coherus Oncology (CHRS) in Q3 2021, closing a stake of 91,886 shares — an estimated $1.27M sold.

Assenagon Asset Management first reported a position in CHRS in Q2 2020 and held it in 5 quarters. The position peaked at $1.27M in Q2 2021. 187 funds tracked by Wall St. Rank hold CHRS as of Q3 2021.

  • Assenagon Asset Management reported no remaining Coherus Oncology position as of Q3 2021 after selling out during the quarter.
  • Assenagon Asset Management sold 91,886 Coherus Oncology shares in Q3 2021, an estimated $1.27M.
  • Assenagon Asset Management first reported a position in Coherus Oncology in Q2 2020 and held it in 5 quarters.
  • Assenagon Asset Management's Coherus Oncology position peaked at $1.27M in Q2 2021.
  • 187 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2021.

Based on Assenagon Asset Management's 13F filing for Q3 2021, filed 19 Oct 2021.